Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

被引:3
作者
Barr, Renae K.
Barber, Bryce W. [2 ]
Tait, Jessica R. [2 ]
Landersdorfer, Cornelia B. [2 ]
Salman, Sam [1 ,3 ,4 ]
Musk, Gabrielle C. [5 ]
Page-Sharp, Madhu [6 ]
Batty, Kevin T. [6 ]
Kado, Joseph [1 ]
Manning, Laurens [1 ,4 ,7 ]
Carapetis, Jonathan R. [1 ,4 ,8 ,10 ]
Boyd, Ben J. [2 ,9 ]
机构
[1] Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Nedlands, WA, Australia
[2] Monash Inst Pharmaceut Sci, Parkville, Vic, Australia
[3] PathWest Lab Med, Clin Pharmacol & Toxicol Unit, Nedlands, WA, Australia
[4] Univ Western Australia, Med Sch, Crawley, WA, Australia
[5] Univ Western Australia, Anim Care Serv, Crawley, WA, Australia
[6] Curtin Univ, Curtin Med Sch, Bentley, WA, Australia
[7] Fiona Stanley Hosp, Dept Infect Dis, Murdoch, WA, Australia
[8] Perth Childrens Hosp, Dept Infect Dis, Nedlands, WA, Australia
[9] Univ Copenhagen, Dept Pharm, Univ Pk 2, DK-2100 Copenhagen, Denmark
[10] Perth Childrens Hosp, Telethon Kids Inst, Northern Entrance,15 Hosp Ave, Nedlands, WA 6009, Australia
基金
英国医学研究理事会;
关键词
Benzathine penicillin G; Rheumatic heart disease; Secondary prophylaxis; long acting implant; Polycaprolactone; Dissolution; in vivo release; FOREIGN-BODY REACTION; INTRAMUSCULAR INJECTION; PHARMACOKINETICS; PREVENTION; FEVER; POLYMERS; BURDEN; YOUNG;
D O I
10.1016/j.ejpb.2023.06.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Regular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.Methods: In this study we developed and evaluated a slow release implant with potential for substantially extended treatment. The side wall of a solid drug rich core was coated with polycaprolactone which acts as an impermeable barrier. The exposed surfaces at the ends of the implant defined the release surface area, and the in vitro release rate of drug was proportional to the exposed surface area across implants of differing diameter. The in vivo pharmacokinetics and tolerability of the implants were evaluated in a sheep model over 9 weeks after subcutaneous implantation.Results: The absolute release rates obtained for the poorly water-soluble benzathine salt were dependent on the exposed surface area demonstrating the impermeability of the wall of the implant. The implants were well tolerated after subcutaneous implantation in a sheep model, without adverse effects at the implantation site. Gross structural integrity was maintained over the course of the study, with erosion limited to the dual-exposed ends. Steady release of penicillin G was observed over the 9 weeks and resulted in approximately constant plasma concentrations close to accepted target concentrations.Conclusion: In principle, a long acting BPG implant is feasible as an alternative to i.m. injections for secondary prophylaxis of RHD. However, large implant size is currently a significant impediment to clinical utility and acceptability.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 54 条
[1]  
[Anonymous], 2022, Acute Rheumatic Fever: Information For Clinicians
[2]  
Australian Government, 2013, AUSTR COD CAR US AN
[3]  
Barber B.W., 2023, DEV SUSTAINED RELEAS
[4]   Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease [J].
Beaton, Andrea ;
Okello, Emmy ;
Rwebembera, Joselyn ;
Grobler, Anneke ;
Engelman, Daniel ;
Alepere, Juliet ;
Canales, Lesley ;
Carapetis, Jonathan ;
DeWyer, Alyssa ;
Lwabi, Peter ;
Mirabel, Mariana ;
Mocumbi, Ana O. ;
Murali, Meghna ;
Nakitto, Miriam ;
Ndagire, Emma ;
Nunes, Maria C. P. ;
Omara, Isaac O. ;
Sarnacki, Rachel ;
Scheel, Amy ;
Wilson, Nigel ;
Zimmerman, Meghan ;
Zuhlke, Liesl ;
Karthikeyan, Ganesan ;
Sable, Craig A. ;
Steer, Andrew C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03) :230-240
[5]   Contraceptive devices: subcutaneous delivery systems [J].
Benagiano, Giuseppe ;
Gabelnick, Henry ;
Farris, Manuela .
EXPERT REVIEW OF MEDICAL DEVICES, 2008, 5 (05) :623-637
[6]   Serum Penicillin G Levels Are Lower Than Expected in Adults within Two Weeks of Administration of 1.2 Million Units [J].
Broderick, Michael P. ;
Hansen, Christian J. ;
Russell, Kevin L. ;
Kaplan, Edward L. ;
Blumer, Jeffrey L. ;
Faix, Dennis J. .
PLOS ONE, 2011, 6 (10)
[7]   The global burden of group A streptococcal diseases [J].
Carapetis, JR ;
Steer, AC ;
Mulholland, EK ;
Weber, M .
LANCET INFECTIOUS DISEASES, 2005, 5 (11) :685-694
[8]   Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? [J].
Carapetis, JR ;
Currie, BJ ;
Mathews, JD .
EPIDEMIOLOGY AND INFECTION, 2000, 124 (02) :239-244
[9]   Interleukin 17 and senescent cells regulate the foreign body response to synthetic material implants in mice and humans [J].
Chung, Liam ;
Maestas, David R., Jr. ;
Lebid, Andriana ;
Mageau, Ashlie ;
Rosson, Gedge D. ;
Wu, Xinqun ;
Wolf, Matthew T. ;
Tam, Ada J. ;
Vanderzee, Isabel ;
Wang, Xiaokun ;
Andorko, James, I ;
Zhang, Hong ;
Narain, Radhika ;
Sadtler, Kaitlyn ;
Fan, Hongni ;
Cihakova, Daniela ;
Le Saux, Claude Jourdan ;
Housseau, Franck ;
Pardoll, Drew M. ;
Elisseeff, Jennifer H. .
SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (539)
[10]   Re-evaluating current antibiotic therapy [J].
Craig, WA .
RESPIRATORY MEDICINE, 2001, 95 :S14-S21